Skip to main content
Erschienen in: Rheumatology International 4/2005

01.05.2005 | Original Article

A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity

verfasst von: Yesim Akkoc, Altinay Goksel Karatepe, Servet Akar, Yesim Kirazli, Nurullah Akkoc

Erschienen in: Rheumatology International | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to develop a Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and assess its reliability, validity, and sensitivity to change. The Turkish version was obtained after a translation and back-translation process. Seventy-one patients with ankylosing spondylitis were assessed with it. To assess its validity, patients were also evaluated with the Turkish version of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Metrology Index (BASMI), the Bath Ankylosing Spondylitis Patient Global Score (BAS-G), and physicians’ assessments of disease activity. Over 24 h, the Turkish BASDAI did not show significant differences between the two assessments (P>0.05). Correlations were found between BASDAI and all of the evaluation parameters except BASMI (P<0.01). Both BASDAI and BASMI showed significant improvements after 8-week home exercise programmes. The results of this study show that the Turkish version of the BASDAI is reliable, valid, and sensitive to change.
Literatur
1.
Zurück zum Zitat Russell AS (1998) Ankylosing spondylitis: history. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, London, pp 1–2 Russell AS (1998) Ankylosing spondylitis: history. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, London, pp 1–2
2.
Zurück zum Zitat Calin A (1987) Editorial. Assessing disease activity in AS. Lancet 1:1072PubMed Calin A (1987) Editorial. Assessing disease activity in AS. Lancet 1:1072PubMed
3.
Zurück zum Zitat Taylor HG, Wardle T, Beswick EJ et al (1991) The relationship of clinical and laboratory measurements to radiological change in AS. Br J Rheumatol 30:330–335PubMed Taylor HG, Wardle T, Beswick EJ et al (1991) The relationship of clinical and laboratory measurements to radiological change in AS. Br J Rheumatol 30:330–335PubMed
4.
Zurück zum Zitat Calin A (1995) The individual with ankylosing spondylitis: defining disease status and impact of illness. Br J Rheumatol 34:663–672PubMed Calin A (1995) The individual with ankylosing spondylitis: defining disease status and impact of illness. Br J Rheumatol 34:663–672PubMed
5.
Zurück zum Zitat Pyle KD, Laurent MR, Salmond CE, Best MJ, Pyle EA, Moloney RO (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30:29–34PubMed Pyle KD, Laurent MR, Salmond CE, Best MJ, Pyle EA, Moloney RO (1991) Clinical assessment of ankylosing spondylitis: a study of observer variation in spinal measurements. Br J Rheumatol 30:29–34PubMed
6.
Zurück zum Zitat Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966–970PubMed Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966–970PubMed
7.
Zurück zum Zitat Kennedy L, Jenkinson T, Mallorie T, Whitelock H, Garrett S (1995) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34:767–770PubMed Kennedy L, Jenkinson T, Mallorie T, Whitelock H, Garrett S (1995) Ankylosing spondylitis: the correlation between a new metrology score and radiology. Br J Rheumatol 34:767–770PubMed
8.
Zurück zum Zitat Mander M, Simpson JM, McLennan A, Walker D, Goodacre JA, Carson Dick W (1987) Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46:197–202PubMed Mander M, Simpson JM, McLennan A, Walker D, Goodacre JA, Carson Dick W (1987) Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 46:197–202PubMed
9.
Zurück zum Zitat Kennedy LG, Edmuns L, Calin A (1993) The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol 20:688–692PubMed Kennedy LG, Edmuns L, Calin A (1993) The natural history of ankylosing spondylitis. Does it burn out? J Rheumatol 20:688–692PubMed
10.
Zurück zum Zitat Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291PubMed
11.
Zurück zum Zitat Claudepierre P, Sibilia J, Goupille P, Flipo RM, Wendling D, Eulry F, Clerc D, Berthelot JM, Vergne P, Roudot-Thoraval F, Larget-Piet B, Chevalier X (1997) Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 24:1954–1958PubMed Claudepierre P, Sibilia J, Goupille P, Flipo RM, Wendling D, Eulry F, Clerc D, Berthelot JM, Vergne P, Roudot-Thoraval F, Larget-Piet B, Chevalier X (1997) Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 24:1954–1958PubMed
12.
Zurück zum Zitat Waldner A, Cronstedt H, Stenström CH (1999) The Swedish version of Bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol 28 [Suppl 111]:10–16 Waldner A, Cronstedt H, Stenström CH (1999) The Swedish version of Bath ankylosing spondylitis disease activity index. Reliability and validity. Scand J Rheumatol 28 [Suppl 111]:10–16
13.
Zurück zum Zitat Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J (2003) Adaptation and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 62:264–273PubMed Brandt J, Westhoff G, Rudwaleit M, Listing J, Zink A, Braun J, Sieper J (2003) Adaptation and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany. Z Rheumatol 62:264–273PubMed
14.
Zurück zum Zitat Cardiel MH, Londono JD, Gutierrez E, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R (2003) Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21:451–458PubMed Cardiel MH, Londono JD, Gutierrez E, Pacheco-Tena C, Vazquez-Mellado J, Burgos-Vargas R (2003) Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21:451–458PubMed
15.
Zurück zum Zitat van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMed van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368PubMed
16.
Zurück zum Zitat Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285PubMed
17.
Zurück zum Zitat Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66–71 Jones SD, Steiner A, Garrett SL, Calin A (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35:66–71
18.
Zurück zum Zitat Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21:1694–1698PubMed
19.
Zurück zum Zitat Scalapino KL, Davis JC Jr (2003) The treatment of ankylosing spondylitis. Clin Exp Med 2:159–165CrossRefPubMed Scalapino KL, Davis JC Jr (2003) The treatment of ankylosing spondylitis. Clin Exp Med 2:159–165CrossRefPubMed
20.
Zurück zum Zitat Haywood KL, Garratt AM, Dziedzic K, Dawes PT (2002) Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 41:1380–1387 Haywood KL, Garratt AM, Dziedzic K, Dawes PT (2002) Generic measures of health-related quality of life in ankylosing spondylitis: reliability, validity and responsiveness. Rheumatology (Oxford) 41:1380–1387
21.
Zurück zum Zitat Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS (2002) A six-month randomised, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766–773CrossRefPubMed Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS (2002) A six-month randomised, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766–773CrossRefPubMed
22.
Zurück zum Zitat Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352 Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, Thriene W, Sieper J, Braun J (2000) Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352
Metadaten
Titel
A Turkish version of the Bath Ankylosing Spondylitis Disease Activity Index: reliability and validity
verfasst von
Yesim Akkoc
Altinay Goksel Karatepe
Servet Akar
Yesim Kirazli
Nurullah Akkoc
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 4/2005
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-003-0432-y

Weitere Artikel der Ausgabe 4/2005

Rheumatology International 4/2005 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.